Iovance Biotherapeutics
 | This article needs additional citations for verification. (November 2019) |
 | |
| Formerly | Lion Biotechnologies, Inc. |
|---|---|
| Company type | Public |
| |
| Industry | |
| Founded | 2007 |
| Headquarters | San Carlos, California, U.S. |
Key people | Steven Rosenberg |
Number of employees | 319 (December 31, 2021) |
| Website | iovance |
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]
History
[edit]The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.[3]
In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[4]
See also
[edit]References
[edit]- ^ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
- ^ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
- ^ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
- ^ Mullard, Asher (2024-02-19). "FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers". Nature Reviews Drug Discovery. doi:10.1038/d41573-024-00035-1. PMID 38374249.
External links
[edit]- Official website
- Business data for Iovance Biotherapeutics, Inc.:
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |